公开(公告)号：US20110054029A1

公开(公告)日：2011-03-03

申请号：US12823945

申请日：2010-06-25

申请人： Eric H. Kuhrts

发明人： Eric H. Kuhrts

IPC分类号： A61K31/202 ,  A61P35/00 ,  A61P3/04 ,  A61P9/00 ,  A61P3/06 ,  A61P25/00 ,  A61P27/02

CPC分类号： A23L33/12 ,  A23L33/10

摘要： Water-soluble dietary fatty acid formulations, solutions, and methods for increasing the water solubility and/or bioavailability of dietary fatty acids, as well as methods for treating various diseases are disclosed.

摘要翻译： 公开了用于增加膳食脂肪酸的水溶性和/或生物利用度的水溶性膳食脂肪酸制剂，溶液和方法，以及用于治疗各种疾病的方法。

公开(公告)号：US07279186B2

公开(公告)日：2007-10-09

申请号：US11452095

申请日：2006-06-12

申请人： Eric H. Kuhrts

发明人： Eric H. Kuhrts

IPC分类号： A01N65/00

CPC分类号： A61K36/185 ,  A61K31/12 ,  A61K2300/00

摘要： Disclosed are novel anti-inflammatory pharmaceutical compositions and related methods that exhibit potent and selective inhibition of the cycloooxygenase-2 (COX-2) enzyme. The formulation can comprise a hops extract that exhibits COX-2 selectivity as defined by dividing the IC50 COX-2/IC50COX-1 concentrations that are determined by testing with the William Harvey Whole Blood Assay (WHMA), and can fall within the range of 0.011 to 0.2. Such compositions may also optionally contain high levels of alpha acids and low levels of beta acids, some flavonoid compounds, and virtually no essential oils. Such compositions are useful for treating conditions that manifest as inflammatory pain, or are impacted by the COX-2 enzyme. The recited compositions are particularly beneficial for treating osteoarthritis and rheumatoid arthritis, and can be used for chronic pain with reduced gastric side-effects.

摘要翻译： 公开了显示对环氧合酶-2（COX-2）酶的有效和选择性抑制的新型抗炎药物组合物和相关方法。 制剂可以包含表现出COX-2选择性的啤酒花提取物，其通过将通过用William Harvey全血分析（WHMA）测试确定的IC 50 COX-2 / IC 50COX-1浓度除以定义，并且可以落在 0.011〜0.2。 此类组合物还可任选地含有高水平的α酸和低水平的β酸，一些类黄酮化合物，并且实际上不含有精油。 这些组合物可用于治疗表现为炎症性疼痛或受COX-2酶影响的病症。 所列举的组合物对于治疗骨关节炎和类风湿性关节炎是特别有益的，并且可以用于减少胃副作用的慢性疼痛。

公开(公告)号：US06475530B1

公开(公告)日：2002-11-05

申请号：US09684697

申请日：2000-10-04

申请人： Eric H. Kuhrts

发明人： Eric H. Kuhrts

IPC分类号： A01N6500

CPC分类号： A61K45/06 ,  A61K31/74 ,  A61K36/17 ,  A61K36/53 ,  A61K36/539 ,  A61K36/704 ,  A61K36/752 ,  A61K36/76 ,  A61K36/82 ,  A61K36/9066 ,  A61K36/9068 ,  A61K2300/00

摘要： Dislcosed are methods and compositions for producing weight loss in a mammal by administration of a composition containing a weight loss effective amount of a noradrenaline stimulating compound such as ephedrine, mahuang (a plant source of ephedrine alkaloids), citrus aurantium (bitter orange), synephrine, norephedrine, psuedophedrine, a methylxanthine, such as caffeine or guarana, and a botanical COX inhibitor such as resveratrol polygonum cuspidatum, scutellaria baicalensis, turmeric, curcumin, rosmary, green tea, ocimum sanctum (holy basil), or ginger, instead of an NSAID such as aspirin, and optionally a free fatty acid reducing compound. The thermogenic formula is coupled with a growth hormone stimulating formulation containing L-arginine or L-omithine, L-lysine, and a free fatty acid reducing agent such as nicotinic acid. The thermogenic formula would preferably be administered in the daytime, and the growth hormone producing formula at nighttime. The two compositions form a system of AM and PM weight loss strategy for the therapeutic intervention of obesity.

摘要翻译： 不适用的是通过给药含有减肥有效量的去甲肾上腺素刺激化合物如麻黄碱，麻黄（麻黄碱生物碱的植物来源），柑橘ium（苦橙），辛伐他汀 ，去甲麻黄碱，伪麻黄素，甲基黄嘌呤，如咖啡因或瓜拉那，以及植物性COX抑制剂，如白藜芦醇，黄芩，姜黄，姜黄素，玫瑰，绿茶，最佳圣地（圣罗勒）或姜， 非甾体抗炎药如阿司匹林，以及任选的游离脂肪酸还原化合物。 生热配方与含有L-精氨酸或L-鸟氨酸，L-赖氨酸和游离脂肪酸还原剂如烟酸的生长激素刺激制剂相结合。 生热配方优选在白天施用，并且在夜间施用生长激素生成配方。 这两种组合物形成了用于肥胖的治疗性干预的AM和PM减肥策略的系统。

公开(公告)号：US5096714A

公开(公告)日：1992-03-17

申请号：US440730

申请日：1989-11-22

申请人： Eric H. Kuhrts

发明人： Eric H. Kuhrts

IPC分类号： A61K9/00 ,  A61K9/16 ,  A61K9/22 ,  A61K31/715 ,  A61K33/06 ,  A61K33/10 ,  A61K36/185 ,  A61K36/48 ,  A61K36/481 ,  A61K36/483 ,  A61K36/68 ,  A61K47/12 ,  A61K47/26 ,  A61K47/36

CPC分类号： A61K9/0095 ,  A61K31/715 ,  A61K33/06 ,  A61K33/10 ,  A61K36/185 ,  A61K36/48 ,  A61K36/481 ,  A61K36/483 ,  A61K36/68 ,  A61K47/12 ,  Y10S514/96

摘要： A prolonged-release unit dosage formulation or pharmaceutical composition, preferably in tablet form, is described. The composition consists essentially of a gel-forming dietary fiber, a biologically-absorbable drug or other active therapeutic agent, and certain specific disintegrants, namely, a physiologically-acceptable edible acid and a mineral salt which releases a physiologically-acceptable gas upon ingestion, preferably carbon dioxide, e.g., a mineral carbonate or bicarbonate, and advantageously dextrose or like soluble sugar. The dietary fiber-containing composition, when compressed into a tablet together with the drug and the specific disintegrants, provides a unique and efficient prolonged-action drug-delivery system.

摘要翻译： 描述了优选片剂形式的延长释放单位剂量制剂或药物组合物。 该组合物基本上由形成凝胶的膳食纤维，生物可吸收药物或其它活性治疗剂以及某些特定的崩解剂组成，即生理上可接受的食用酸和摄入时释放生理上可接受的气体的矿物盐， 优选二氧化碳，例如无机碳酸盐或碳酸氢盐，并且有利地是葡萄糖或类似的可溶性糖。 含膳食纤维的组合物当与药物和特定的崩解剂一起压制成片剂时，提供了独特且有效的长效药物递送系统。

公开(公告)号：US5993860A

公开(公告)日：1999-11-30

申请号：US969810

申请日：1997-11-13

申请人： Eric H. Kuhrts ,  David R. Friend ,  Karen Yu ,  Jagdish Parasrampuria

发明人： Eric H. Kuhrts ,  David R. Friend ,  Karen Yu ,  Jagdish Parasrampuria

IPC分类号： A61K9/20 ,  A61K31/192 ,  A61K9/16 ,  A61K47/30 ,  A61K47/36

CPC分类号： A61K31/616 ,  A61K31/192 ,  A61K9/205 ,  Y10S514/922 ,  Y10S514/951 ,  Y10S514/96 ,  Y10S514/974

摘要： An oral-delivery pharmaceutical composition for reducing the gastric irritation effect of an NSAID in the upper GI tract of a mammal. The composition includes (a) a mucosal protective amount of a pharmaceutically-acceptable hydrocolloid gum obtainable from higher plants, (b) a dispersion-enhancing amount of another excipient and (c) a therapeutically-effective amount of an NSAID. Also disclosed is a process for preparing the composition and a method for reducing the gastric irritation effect of the NSAID by administering the composition. Also, disclosed is a composition particularly useful for preparing an aqueous suspension.

摘要翻译： 一种口服递送药物组合物，其用于降低哺乳动物上GI肠道中的NSAID的胃刺激作用。 组合物包括（a）可从高等植物获得的粘膜保护量的药学可接受的水胶体胶，（b）分散增强量的另一赋形剂和（c）治疗有效量的NSAID。 还公开了制备该组合物的方法和通过施用该组合物来降低NSAID的胃刺激作用的方法。 此外，公开了特别可用于制备水性悬浮液的组合物。

公开(公告)号：US5981555A

公开(公告)日：1999-11-09

申请号：US937669

申请日：1997-09-26

申请人： Eric H. Kuhrts ,  L. Jackson Roberts, II ,  Jason D. Morrow

发明人： Eric H. Kuhrts ,  L. Jackson Roberts, II ,  Jason D. Morrow

IPC分类号： A61K31/455 ,  A61K31/54 ,  A61K31/60 ,  A61K31/715 ,  A61K31/33

CPC分类号： A61K31/60 ,  A61K31/455 ,  A61K31/54 ,  A61K31/621 ,  Y10S514/823

摘要： The present invention concerns composition, kits and methods for reducing the flushing effect (cutaneous erythema) of an antilipemic drug, for treating hyperlipemia, for improving the effectiveness of an anti-platelet aggregating drug (e.g., in nonresponders) and for treating thrombosis. The present compositions and kits for reducing the flushing effect and for treating hyperlipemia contain an antilipemic drug (such as niacin) and either a sustained release NSAID (such as aspirin) or an NSAID and a carboxylic acid compound other than the NSAID and antilipemic drug. The kits contain (a) pre-dosages of the NSAID and optional carboxylic acid compound and (b) an antilipemic dosage of the antilipemic drug, which optionally may be combined with NSAID and optional carboxylic acid compound in an amount effective to maintain the reduction of the flushing effect. The present method of treating hyperlipemia comprises predosing the patient with a sustained release NSAID or an NSAID and a carboxylic acid compound other than the NSAID and antilipemic drug at least 2 hours before administering the antilipemic drug. The present compositions and kits for increasing the effectiveness of an anti-platelet aggregating drug contain an NSAID such as aspirin, niacin or a congener thereof, and optionally, a carboxylic acid other than the NSAID, such as citric acid.

摘要翻译： 本发明涉及用于降低抗血脂药物的冲洗作用（皮肤红斑），用于治疗高脂血症，改善抗血小板聚集药物（例如，在无应答者中）和用于治疗血栓形成的效果的组合物，试剂盒和方法。 用于降低冲洗效果和用于治疗高脂血症的本发明组合物和试剂盒含有抗血脂药物（例如烟酸）和持续释放的NSAID（例如阿司匹林）或NSAID和除NSAID和抗脂药物之外的羧酸化合物。 试剂盒包含（a）NSAID和任选的羧酸化合物的预先剂量和（b）抗脂药物的抗血药剂量，其任选地可以与NSAID和任选的羧酸化合物组合，其量有效地维持 冲洗效果。 本发明治疗高脂血症的方法包括在施用抗血脂药物前至少2小时预先给予具有持续释放NSAID或NSAID和除NSAID和抗脂药物之外的羧酸化合物的患者。 用于增加抗血小板聚集药物的有效性的本发明组合物和试剂盒含有NSAID，例如阿司匹林，烟酸或其同类物，以及任选的除NSAID之外的羧酸，例如柠檬酸。

公开(公告)号：US5945295A

公开(公告)日：1999-08-31

申请号：US995480

申请日：1997-12-22

申请人： L. Jackson Roberts, II ,  Jason D. Morrow ,  Eric H. Kuhrts

发明人： L. Jackson Roberts, II ,  Jason D. Morrow ,  Eric H. Kuhrts

IPC分类号： G01N33/88 ,  G01N33/03 ,  C07C61/06 ,  C12Q1/26

CPC分类号： G01N33/88

摘要： This invention relates to a method to assess food spoilage ex vivo by quantification of prostanoid compounds and their metabolites produced by a noncyclooxygenase free radical catalyzed mechanism.

摘要翻译： 本发明涉及一种通过定量前列腺素类化合物及其通过非环氧合酶自由基催化机制产生的代谢物来评估食物变质的方法。

公开(公告)号：US5445826A

公开(公告)日：1995-08-29

申请号：US167325

申请日：1993-12-14

申请人： Eric H. Kuhrts

发明人： Eric H. Kuhrts

IPC分类号： A61K9/00 ,  A61K9/46 ,  A61K31/715 ,  A61K33/06 ,  A61K33/10 ,  A61K36/02 ,  A61K36/185 ,  A61K36/48 ,  A61K36/481 ,  A61K36/483 ,  A61K36/68 ,  A61K47/12 ,  A61K9/48

CPC分类号： A61K9/0095 ,  A61K31/715 ,  A61K33/06 ,  A61K33/10 ,  A61K36/02 ,  A61K36/185 ,  A61K36/48 ,  A61K36/481 ,  A61K36/483 ,  A61K36/68 ,  A61K47/12

摘要： A prolonged-release unit dosage formulation or pharmaceutical composition, preferably in tablet form, is described. The composition consists essentially of a gel-forming fiber, preferably hydrocolloid-coated, a biologically-absorbable drug or other active therapeutic agent which is also preferably hydrocolloid-coated, a mineral salt which releases a physiologically-acceptable gas upon ingestion, preferably carbon dioxide, e.g., a mineral carbonate or bicarbonate, and optionally an organic or phosphoric acid and a dextrose or like soluble sugar. The fiber-containing composition, when in the form of a tablet or other unit dosage form together with the drug or agent and the stated disintegrants, provides a unique, efficient and controllable prolonged-action drug-delivery system.

摘要翻译： 描述了优选片剂形式的延长释放单位剂量制剂或药物组合物。 该组合物基本上由形成凝胶的纤维组成，优选为水胶体包被的生物可吸收药物或其它活性治疗剂，其还优选为水胶体涂覆的，摄取后释放生理上可接受的气体的矿物盐，优选二氧化碳 ，例如矿物碳酸盐或碳酸氢盐，以及任选的有机或磷酸和葡萄糖或类似的可溶性糖。 含有纤维的组合物当以片剂或其它单位剂型形式与药物或试剂以及所述的崩解剂一起提供了独特的，有效的和可控制的延长作用的药物递送系统。

公开(公告)号：US4911917A

公开(公告)日：1990-03-27

申请号：US212607

申请日：1988-06-28

申请人： Eric H. Kuhrts

发明人： Eric H. Kuhrts

IPC分类号： A61K33/06

CPC分类号： A61K33/06 ,  Y10S514/922

摘要： An antihyperlipidemic pharmaceutical or dietary supplement composition for oral use consisting essentially of a combination of niacin and a physiologically-acceptable magnesium salt, and a method of lowering cholesterol levels with such oral pharmaceutical composition, or by the simultaneous oral administration of the active ingredients thereof, which eliminates the usual undesirable flushing side effect of niacin, is disclosed.

摘要翻译： 用于口服使用的抗高血脂药物或膳食补充剂组合物基本上由烟酸和生理上可接受的镁盐的组合组成，以及使用这种口服药物组合物降低胆固醇水平的方法，或通过同时口服其活性成分， 其消除了烟酸的通常不期望的冲洗副作用。

公开(公告)号：US20230059124A1

公开(公告)日：2023-02-23

申请号：US17812960

申请日：2022-07-15

申请人： Eric H Kuhrts

发明人： Eric H Kuhrts

IPC分类号： A61K31/05 ,  A61P37/04 ,  A61K45/06

摘要： A method for simulating the activity of the bitter taste receptor TAS2R38 using a prenylflavonoid such as xanthohumol, or an extract thereof. A method of stimulating the innate immune system and prevention of upper airway infections in the body can include a prenylflavonoid extract such as xanthohumol in a solubilized system such as a spray, mouth rinse, beverage, fast dissolving dosage form, or any other means of making contact of the molecule with the receptor in the mouth or nasal passages. Also included is a method for lengthening the lifespan of humans or animals by stimulating the TAS2R38 taste receptor with the prenylflavonoid xanthohumol.